Clinical trial · Observational
Lapatinib Resistance in Patients With Breast Cancer
Study of Resistance Mechanisms Against Lapatinib in Patients With ErbB-2-Positive Breast Cancers
NCT00898573CI-TRIAL-00019294withdrawnClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Studying samples of tumor tissue and blood from patients with cancer in the laboratory may help doctors learn more about cancer and the development of drug resistance in patients. PURPOSE: This research study is looking at lapatinib resistance in patients with breast cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (9)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| cell sorting | Other | — | UNRESOLVED |
| fluorescence in situ hybridization | Genetic | — | UNRESOLVED |
| gene expression analysis | Genetic | — | UNRESOLVED |
| immunohistochemistry staining method | Other | — | UNRESOLVED |
| laboratory biomarker analysis | Other | — | UNRESOLVED |
| lapatinib ditosylate | Drug | Lapatinib | ALIAS |
| mutation analysis | Genetic | — | UNRESOLVED |
| polymerase chain reaction | Genetic | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (3)
- measure
- Secondary ErbB2 mutations
- measure
- ErbB2 copy number changes and expression levels
- measure
- Abnormalities of other pathways (e.g., c-MET and PI3K) as potential mechanisms of resistance
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Pathologically confirmed invasive breast cancer * ErbB2-positive disease * Has received or is currently receiving lapatinib ditosylate * Documented clinical benefit while receiving lapatinib ditosylate (e.g., stable disease of ≥ 12 weeks duration OR a radiographic response) * Must have tumor tissue samples available for research studies * Hormone receptor status not specified PATIENT CHARACTERISTICS: * Menopausal status not specified * Not pregnant\* * Coagulation profile normal\* * Platelet count \> 100,000/mm³\* NOTE: \*For patients requiring a post-treatment biopsy PRIOR CONCURRENT THERAPY: * See Disease Characteristics * Concurrent chemotherapy or trastuzumab (Herceptin®) allowed * No concurrent anticoagulants, including warfarin or low-molecular weight heparin\* * No concurrent antiplatelet therapy, including aspirin, clopidogrel, or other antiplatelet agents\* NOTE: \*For patients requiring a post-treatment biopsy
References
Publications (0)
Data not yet available
No reference posted for this study.